2017
GBM radiosensitizers: dead in the water…or just the beginning?
Bindra RS, Chalmers AJ, Evans S, Dewhirst M. GBM radiosensitizers: dead in the water…or just the beginning? Journal Of Neuro-Oncology 2017, 134: 513-521. PMID: 28762004, DOI: 10.1007/s11060-017-2427-7.Peer-Reviewed Original ResearchConceptsPre-clinical evidenceNovel therapeutic approachesGBMs recurDevelopment of radiosensitizersClinical trialsTherapeutic approachesDNA damage response inhibitorsLocal controlPrimary siteDNA repair inhibitorsPotent agentOxidative stressRadiosensitizerRepair inhibitorsRadiosensitizationInhibitorsRadiotherapyClinicHypoxiaTrials
1986
Radiosensitization, pharmacokinetics, and toxicity of a 2-nitroimidazole nucleoside (RA-263).
Agrawal K, Rupp W, Rockwell S. Radiosensitization, pharmacokinetics, and toxicity of a 2-nitroimidazole nucleoside (RA-263). Radiation Research 1986, 105: 227-39. PMID: 3754053, DOI: 10.2307/3576548.Peer-Reviewed Original ResearchConceptsEMT6 mammary tumorsRapid alpha phaseSlower beta phaseMammary tumor cellsEffect of radiosensitizationRadiation survival curvesTumor concentrationsMammary tumorsPotent radiosensitizerPharmacokinetic dataHypoxic Chinese hamster cellsSurvival curvesTumor cellsHypoxic cellsMisonidazoleHypoxic cell toxicityRadiosensitization experimentsSignificant decreaseHypoxic conditionsRadiosensitization activityExtrapolation numberEquimolar basisPharmacokineticsRadiosensitizationLD50 test
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply